MAIA Biotechnology

Telomeres on chromosomes
#DNA #Lung cancer #MAIA Biotechnology #Oncology #Phase II trial

Positive efficacy updates for Phase II trial in non-small cell lung cancer

MAIA Biotechnology has shared positive updated data from its THIO-101 Phase II clinical trial evaluating its lead candidate, THIO, in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.  In the trial, THIO was sequenced with Regeneron’s immune checkpoint inhibitor… Read More

#Cancer Research #News

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News